Oncoinvent AS, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
PLoS One. 2021 Mar 4;16(3):e0248133. doi: 10.1371/journal.pone.0248133. eCollection 2021.
Alpha-particle emitting radionuclides continue to be the subject of medical research because of their high energy and short range of action that facilitate effective cancer therapies. Radium-224 (224Ra) is one such candidate that has been considered for use in combating micrometastatic disease. In our prior studies, a suspension of 224Ra-labeled calcium carbonate (CaCO3) microparticles was designed as a local therapy for disseminated cancers in the peritoneal cavity. The progenies of 224Ra, of which radon-220 (220Rn) is the first, together contribute three of the four alpha particles in the decay chain. The proximity of the progenies to the delivery site at the time of decay of the 224Ra-CaCO3 microparticles can impact its therapeutic efficacy. In this study, we show that the diffusion of 220Rn was reduced in labeled CaCO3 suspensions as compared with cationic 224Ra solutions, both in air and liquid volumes. Furthermore, free-floating lead-212 (212Pb), which is generated from released 220Rn, had the potential to be re-adsorbed onto CaCO3 microparticles. Under conditions mimicking an in vivo environment, more than 70% of the 212Pb was adsorbed onto the CaCO3 at microparticle concentrations above 1 mg/mL. Further, the diffusion of 220Rn seemed to occur whether the microparticles were labeled by the surface adsorption of 224Ra or if the 224Ra was incorporated into the bulk of the microparticles. The therapeutic benefit of differently labeled 224Ra-CaCO3 microparticles after intraperitoneal administration was similar when examined in mice bearing intraperitoneal ovarian cancer xenografts. In conclusion, both the release of 220Rn and re-adsorption of 212Pb are features that have implications for the radiotherapeutic use of 224Ra-labeled CaCO3 microparticles. The release of 220Rn through diffusion may extend the effective range of alpha-particle dose deposition, and the re-adsorption of the longer lived 212Pb onto the CaCO3 microparticles may enhance the retention of this nuclide in the peritoneal cavity.
阿尔法粒子发射放射性核素因其能量高、作用范围短而继续成为医学研究的主题,这有助于进行有效的癌症治疗。镭-224(224Ra)就是这样一种候选物,它已被考虑用于治疗微转移疾病。在我们之前的研究中,设计了一种 224Ra 标记碳酸钙(CaCO3)微球的混悬液,作为治疗腹腔内播散性癌症的局部治疗方法。224Ra 的后代,其中氡-220(220Rn)是第一个,共同贡献衰变链中四个阿尔法粒子中的三个。224Ra-CaCO3 微球衰变时,后代与给药部位的接近程度可能会影响其治疗效果。在这项研究中,我们表明与阳离子 224Ra 溶液相比,220Rn 的扩散在标记的 CaCO3 悬浮液中减少,无论是在空气还是液体体积中。此外,从释放的 220Rn 产生的游离铅-212(212Pb)有可能重新吸附到 CaCO3 微球上。在模拟体内环境的条件下,当 CaCO3 微球浓度高于 1mg/mL 时,超过 70%的 212Pb 被吸附到 CaCO3 上。此外,220Rn 的扩散似乎发生在 224Ra 通过表面吸附标记微球或 224Ra 掺入微球本体时。在携带腹腔卵巢癌异种移植的小鼠中检查后,经腹腔给予不同标记的 224Ra-CaCO3 微球的治疗益处相似。总之,220Rn 的释放和 212Pb 的再吸附是 224Ra 标记 CaCO3 微球放射性治疗应用的重要特征。通过扩散释放 220Rn 可能会扩大阿尔法粒子剂量沉积的有效范围,而更长寿命的 212Pb 重新吸附到 CaCO3 微球上可能会增强该核素在腹腔中的滞留。